Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

(2021) Feng-Hua Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

(2021) David Johnson et al.   ORAL ONCOLOGY

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer

(2021) Caroline Even et al.   CLINICAL CANCER RESEARCH

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

(2021) Yunpeng Yang et al.   LANCET ONCOLOGY

The expanding universe of checkpoint inhibitors for nasopharyngeal cancer

(2021) Brigette B. Y. Ma et al.   NATURE MEDICINE

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

(2021) Hai-Qiang Mai et al.   NATURE MEDICINE

Nasopharyngeal carcinoma: an evolving paradigm

(2021) Kenneth C. W. Wong et al.   Nature Reviews Clinical Oncology

Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?

(2020) Liam Masterson et al.   INTERNATIONAL JOURNAL OF CANCER

The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma

(2020) Jong Chul Park et al.   ORAL ONCOLOGY

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) P. Bossi et al.   ANNALS OF ONCOLOGY

Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).

(2019) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

Nasopharyngeal carcinoma

(2019) Yu-Pei Chen et al.   LANCET

Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives

(2019) Jinyi Lang et al.   Cancer Management and Research

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

(2018) Brigette B.Y. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

(2018) Wenfeng Fang et al.   LANCET ONCOLOGY

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

(2017) Chiun Hsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer

(2017) Oscar Siu Hong Chan et al.   ORAL ONCOLOGY

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER